Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, messages, and whatever else has predictably returned. But what can you do? The world keeps spinning, after all. We have a solution — firing up the coffee kettle for a cup of stimulation. Please feel free to join us while we indulge. Meanwhile, here are some tidbits to help you get started. Hope you have a smashing day and please do keep in touch. …

Purdue Pharma announced late Sunday that it had filed for bankruptcy, marking the collapse of a company that reaped billions of dollars from the sale of its opioid painkiller OxyContin and other drugs, STAT tells us. The bankruptcy is part of a tentative agreement with 24 states and thousands of cities and counties that sought to recover damages incurred by responding to overdoses, fighting drug-related crime, and expanding social services to handle the widespread impact of opioid addiction.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy